16:07 EST Phathom Pharmaceuticals files $500M mixed securities shelf
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PHAT:
- Phathom Pharmaceuticals expects cash to fund operations through end of 2025
- Phathom Pharmaceuticals Reports Third Quarter 2023 Results and Recent Business Updates
- Phathom Pharmaceuticals reports Q3 EPS (76c), consensus (89c)
- Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Treatment of Erosive GERD and Relief of Heartburn Associated with Erosive GERD in Adults
- Phathom Pharmaceuticals Announces FDA Approval of Reformulated Vonoprazan Tablets for VOQUEZNA® TRIPLE PAK® (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA® DUAL PAK® (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults